Ohba M - Search Results

1

Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells.

Matsunaga Y, Yamaoka T, Ohba M, Miura S, Masuda H, Sangai T, Takimoto M, Nakamura S, Tsurutani J. Matsunaga Y, et al. Among authors: ohba m. Antibodies (Basel). 2021 Feb 1;10(1):6. doi: 10.3390/antib10010006. Antibodies (Basel). 2021. PMID: 33535554 Free PMC article.

2

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.

Yamaoka T, Ohba M, Matsunaga Y, Tsurutani J, Ohmori T. Yamaoka T, et al. Among authors: ohba m. J Vis Exp. 2019 Jun 26;(148). doi: 10.3791/59473. J Vis Exp. 2019. PMID: 31305510

3

Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.

Yamaoka T, Arata S, Homma M, Homma T, Kusumoto S, Ando K, Manabe R, Kishino Y, Ohba M, Tsurutani J, Takimoto M, Ohmori T, Sagara H. Yamaoka T, et al. Among authors: ohba m. Int J Mol Sci. 2019 Aug 17;20(16):4021. doi: 10.3390/ijms20164021. Int J Mol Sci. 2019. PMID: 31426531 Free PMC article.

4

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.

Yamaoka T, Ohba M, Ohmori T. Yamaoka T, et al. Among authors: ohba m. Int J Mol Sci. 2017 Nov 15;18(11):2420. doi: 10.3390/ijms18112420. Int J Mol Sci. 2017. PMID: 29140271 Free PMC article. Review.

5

Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells.

Toba-Ichihashi Y, Yamaoka T, Ohmori T, Ohba M. Toba-Ichihashi Y, et al. Among authors: ohba m. Biochem Biophys Rep. 2015 Nov 27;5:1-7. doi: 10.1016/j.bbrep.2015.11.021. eCollection 2016 Mar. Biochem Biophys Rep. 2015. PMID: 28955801 Free PMC article.

6

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.

Yamaoka T, Ohba M, Arata S, Ohmori T. Yamaoka T, et al. Among authors: ohba m. J Vis Exp. 2017 Aug 11;(126):55967. doi: 10.3791/55967. J Vis Exp. 2017. PMID: 28829429 Free PMC article.

7

KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.

Nakatani K, Yamaoka T, Ohba M, Fujita KI, Arata S, Kusumoto S, Taki-Takemoto I, Kamei D, Iwai S, Tsurutani J, Ohmori T. Nakatani K, et al. Among authors: ohba m. Mol Cancer Ther. 2019 Jan;18(1):112-126. doi: 10.1158/1535-7163.MCT-18-0591. Epub 2018 Oct 15. Mol Cancer Ther. 2019. PMID: 30322949

8

Receptor Tyrosine Kinase-Targeted Cancer Therapy.

Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Yamaoka T, et al. Among authors: ohba m. Int J Mol Sci. 2018 Nov 6;19(11):3491. doi: 10.3390/ijms19113491. Int J Mol Sci. 2018. PMID: 30404198 Free PMC article. Review.

9

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Murata Y, Kusumoto S, Ando K, Ishida H, Ohnishi T, Sasaki Y. Yamaoka T, et al. Among authors: ohba m. Mol Cancer Res. 2017 Jul;15(7):915-928. doi: 10.1158/1541-7786.MCR-16-0482. Epub 2017 Mar 13. Mol Cancer Res. 2017. PMID: 28289161

10

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.

Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Yamaoka T, et al. Among authors: ohba m. Mol Cancer Ther. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. Epub 2016 Sep 9. Mol Cancer Ther. 2016. PMID: 27612490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

439 results

Search Page